News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
FDA
Aventis Pharma Obtains Additional Approval for Taxoid Antitumor Agent TAXOTERE Injection
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo (JCN) - Aventis Pharma of the sanofi-aventis Group announced on August 19 that it has obtained additional approval for TAXOTERE Injection, its proprietary taxoid antitumor agent, from the Ministry of Health, Labor and Welfare as of August 18.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Sanofi US
Sanofi (France)
MORE ON THIS TOPIC
Gene therapy
FDA Does 180 on Sarepta, Freeing DMD Gene Therapy for Ambulatory Patients
July 28, 2025
·
2 min read
·
Annalee Armstrong
Duchenne muscular dystrophy
Sarepta Denies Latest Patient Death is Elevidys-Linked as FDA Launches Probe
July 28, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Drug Pricing Just One Point of Confusion Over New FDA Vouchers
July 28, 2025
·
4 min read
·
Dan Samorodnitsky
Gene therapy
Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys
July 25, 2025
·
4 min read
·
Tristan Manalac